Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Non-Randomized Open Labelled Clinical Trial to Evaluate the Safety & Immunogenicity of SARS-COV-2 Vaccine (Vero Cell) Inactivated as A Booster Dose

NCT05172193 is registered in ClinicalTrials.gov with PT. Kimia Farma (Persero) Tbk as lead sponsor.

NCT NCT05172193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05172193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Non-Randomized Open Labelled Clinical Trial to Evaluate the Safety & Immunogenicity of SARS-COV-2 Vaccine (Vero Cell) Inactivated as A Booster Dose
Lead sponsor
PT. Kimia Farma (Persero) Tbk
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2021
Completion date
September 30, 2023
Enrollment
600 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19